NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
Want to see NMTC full AI Analyst Report?
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.00
▼(-17.36% Downside)
Action:Reiterated
Date:05/23/26
The score is weighed down primarily by persistent losses and substantial ongoing cash burn, alongside weak technical momentum with the stock trading below key moving averages. Guidance was reiterated and recent product revenue growth is encouraging, but liquidity pressure and a revenue-restatement event add near-term risk, while valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Strong product revenue growth
Substantial Q2 and YTD product revenue growth demonstrates durable commercial traction for the OneRF system and procedure-driven demand. Persistent adoption at hospitals and epilepsy centers supports a sustainable revenue base and provides a clear path to scale recurring consumable and per‑procedure sales over the next 2–6 months.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means the business currently cannot self‑fund its growth or operating needs. Continued burn raises dependence on external financing, which can constrain strategic choices, slow international rollout or clinical programs, and increase dilution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong product revenue growth
Substantial Q2 and YTD product revenue growth demonstrates durable commercial traction for the OneRF system and procedure-driven demand. Persistent adoption at hospitals and epilepsy centers supports a sustainable revenue base and provides a clear path to scale recurring consumable and per‑procedure sales over the next 2–6 months.
Read all positive factors
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.65M
Dividend YieldN/A
Average Volume (3M)532.45K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth10.98%
EPS Growth41.82%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.87
Shares Outstanding8,619,876
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$9.67Price Target Upside99.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$11.46M
NeuroOne Medical Technologies Business Overview & Revenue Model
Company Description
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephal...
How the Company Makes Money
NeuroOne makes money primarily by selling its neurosurgical electrode products and related accessories to healthcare providers (e.g., hospitals and epilepsy/surgical centers) for use in clinical procedures. Revenue is generated through product sal...
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Neutral
The call conveyed meaningful operational and clinical progress — notably 72% Q2 product revenue growth, publication and clinical wins, ISO audit progress, regained NASDAQ compliance, and no debt — alongside strategic hires and partnership momentum. However, material financial and timing challenges temper the optimism: cash balances declined sharply (~57.6%), there was no license revenue this year (vs. $3.0M prior), six-month net loss widened to $3.5M, and gross margins compressed. Several growth catalysts (international rollout, drug delivery commercial availability, spinal cord stimulation timeline) remain contingent on future milestones or partner actions and thus introduce execution and timing risk. Balancing the clear operational wins against the pronounced near-term liquidity and revenue-recognition headwinds yields a neutral overall view.Positive Updates
Strong Q2 Product Revenue Growth
Product revenue for OneRF brain ablation system grew 72% year-over-year to $2.4M in Q2 FY2026 (from $1.4M in Q2 FY2025); product revenue for the six months ended March 31, 2026 was $5.3M, up 13% year-over-year (from $4.7M).
Negative Updates
Significant Cash Decline
Cash and cash equivalents declined from $6.6M (Sept 30, 2025) to $2.8M (Mar 31, 2026), a decrease of approximately 57.6%, indicating a tighter near-term cash position.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Q2 Product Revenue Growth
Product revenue for OneRF brain ablation system grew 72% year-over-year to $2.4M in Q2 FY2026 (from $1.4M in Q2 FY2025); product revenue for the six months ended March 31, 2026 was $5.3M, up 13% year-over-year (from $4.7M).
Read all positive updates
Company Guidance
The company reiterated prior top-line guidance of roughly 10.5% product revenue growth for fiscal 2026, noting that this outlook excludes any contributions from the drug‑delivery program or the OneRF trigeminal (facial pain) system; drug delivery is targeted for commercial availability in H2 FY26 (sterilization/packaging validation ~3 months) but is expected to come late in the year and not drive material FY26 revenue, while facial‑pain revenue depends on timing of a partnership. For context, Q2 product revenue was $2.4M (up 72% YoY) and product revenue was $5.3M for the six months (up 13%); Q2 product gross profit was $1.3M (53.8% margin) and YTD gross profit $2.9M (54.0%); Q2 operating expenses were $3.4M, Q2 net loss was $2.1M ($0.25/share), cash was $2.8M with $2.4M in receivables expected to convert to cash in Q3, working capital was $5.7M, and the company had no debt.NeuroOne Medical Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.72M | 12.10M | 3.45M | 1.95M | 171.17K | 178.15K |
| Gross Profit | 5.30M | 8.14M | 1.08M | 456.52K | -70.79K | -97.75K |
| EBITDA | -6.66M | -3.01M | -11.84M | -11.76M | -9.91M | -9.80M |
| Net Income | -6.64M | -3.61M | -12.32M | -11.86M | -10.00M | -9.95M |
Balance Sheet | ||||||
| Total Assets | 7.86M | 10.79M | 5.37M | 8.10M | 12.82M | 7.94M |
| Cash, Cash Equivalents and Short-Term Investments | 2.80M | 6.57M | 1.46M | 5.32M | 11.14M | 6.90M |
| Total Debt | 206.97K | 266.81K | 260.16K | 184.40K | 202.90K | 315.67K |
| Total Liabilities | 2.49M | 3.71M | 4.55M | 1.85M | 3.22M | 1.38M |
| Stockholders Equity | 5.37M | 7.07M | 822.01K | 6.25M | 9.60M | 6.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.57M | -2.92M | -11.13M | -13.27M | -7.79M | -8.67M |
| Operating Cash Flow | -7.43M | -2.84M | -11.01M | -12.89M | -7.52M | -8.60M |
| Investing Cash Flow | -133.43K | -81.74K | -120.20K | 2.65M | -3.24M | -67.08K |
| Financing Cash Flow | 9.05M | 8.33M | 7.27M | 7.40M | 12.02M | 11.53M |
NeuroOne Medical Technologies Technical Analysis
Negative
4.84
Price Trends
4.37
Negative
4.56
Negative
4.66
Negative
Market Momentum
-0.28
Positive
35.11
Neutral
15.88
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 4.84 is above the 20-day moving average (MA) of 3.98, above the 50-day MA of 4.37, and above the 200-day MA of 4.66, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 35.11 is Neutral, neither overbought nor oversold. The STOCH value of 15.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $72.34M | -5.08 | 836.32% | ― | 31.90% | -10.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $44.45M | -5.72 | -15.79% | ― | -42.94% | -529.29% | |
44 Neutral | $29.65M | -4.37 | -98.33% | ― | 10.98% | 41.82% | |
39 Underperform | $3.82M | -0.09 | -247.60% | ― | ― | 36.00% |
* Healthcare Sector Average
NMTC
NeuroOne Medical Technologies
3.44
-0.09
-2.66%
SRTS
Sensus Healthcare
2.70
-2.30
-46.00%
ECOR
Electrocore
8.72
3.14
56.27%
MODD
Modular Medical
4.64
-19.78
-81.00%
RBOT
Vicarious Surgical
0.54
-7.33
-93.19%
NeuroOne Medical Technologies Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
NeuroOne Restates Quarterly Results After Revenue Recognition Error
Negative
May 22, 2026
On May 22, 2026, NeuroOne Medical Technologies said it would amend and restate its financial statements for the quarter ended March 31, 2026, after discovering a revenue-recognition error tied to a customer order modification at quarter-end. The r...
Delistings and Listing ChangesRegulatory Filings and Compliance
NeuroOne Regains Nasdaq Compliance After Bid Price Recovery
Positive
May 4, 2026
NeuroOne Medical Technologies disclosed that on May 6, 2025, it received a notice from Nasdaq indicating its common stock had closed below $1.00 per share for 30 consecutive business days, putting the company out of compliance with the exchange...
Executive/Board Changes
NeuroOne Appoints New CFO Amid Planned Leadership Transition
Neutral
Apr 30, 2026
On April 24, 2026, NeuroOne Medical Technologies announced that Chief Financial Officer Ronald McClurg intends to retire from his CFO role effective June 30, 2026, and will remain with the company as a Senior Advisor through December 31, 2026 to s...
Regulatory Filings and ComplianceStock Split
NeuroOne Announces 1-for-6 Reverse Stock Split Implementation
Neutral
Apr 14, 2026
On April 14, 2026, NeuroOne Medical Technologies Corporation filed an amendment to its certificate of incorporation to implement a 1-for-6 reverse stock split of its common stock, following stockholder approval and board authorization at the compa...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
NeuroOne Shareholders Approve Equity Plan and Reverse Split
Neutral
Apr 3, 2026
On February 25, 2026, NeuroOne Medical Technologies’ board adopted, and on April 3, 2026, shareholders approved, an amendment to the company’s 2025 Equity Incentive Plan that immediately adds 1,500,000 shares to the pool and establishe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.